REG - N4 Pharma PLC - Directorate Change

N4 PharmaAnnouncement

08/07/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250708:nRSH0438Qa&default-theme=true

RNS Number : 0438Q  N4 Pharma PLC  08 July 2025

 

8 July 2025

 

N4 Pharma plc

 

("N4 Pharma" or the "Company")

 

Directorate Change

 

N4 Pharma plc (AIM: N4P), the UK biotech developing Nuvec®, its proprietary
gene delivery system to enable advanced therapies for cancer and other
diseases, is pleased to announce the appointment of Edward Wardle as a
Non-Executive Director of the Company with immediate effect.

Edward is joining the Board as a representative of Northern Standard Limited,
which is the Company's largest shareholder. Edward brings board-level
experience of strategy, corporate governance and business development. Having
founded and led multiple businesses, he is currently an investment adviser
with Tracarta Limited and Northern Standard Limited, focusing on critical
industries and cutting-edge technologies, as well as a Senior Business
Development Executive at Ironveld plc. He joined the Board of AIM-listed
TheraCryf plc, the clinical stage drug development company focusing on
neuropsychiatry and oncology, as a Non-Executive Director in May 2025.

Nigel Theobald, Chief Executive Officer of N4 Pharma, said:

"We are delighted to welcome Ed to the Board of N4 Pharma, representing our
largest shareholder. His experience in strategy, corporate governance,
business development, and his background in innovative technologies will be
invaluable as N4 Pharma develops its Nuvec® platform and continues to build
out its data packages to secure licensing opportunities."

 

Edward Wardle commented:

 

"Northern Standard sees a future where N4 Pharma's Nuvec® platform shifts the
paradigm of drug delivery by enabling the evolution of advanced RNA therapies;
where time-consuming, in-clinic injections become something as small as a
pill.  We believe N4 Pharma has the technology, IP, and world-class team
necessary to deliver this future, and are honoured to support them as they
do."

 

- Ends -

 

The following information is disclosed pursuant to Rule 17 and Schedule Two
paragraph (g) of the AIM Rules for Companies in relation to Edward James
Norman Wardle, aged 34:

 

 Current Directorships/Partnerships  Past Directorships/Partnerships (within 5 years)
 TheraCryf PLC

                                   Otherworld Manchester Limited
 The Hammer Organization Limited

                                   Otherworld Birmingham Limited
 Otherworld Piccadilly Limited

 The Dream Corporation Limited*

 Otherworld Dublin Limited

*Per Schedule Two paragraph (g)(v) of the AIM Rules for Companies - The Dream
Corporation Limited is currently undergoing creditors' voluntary liquidation,
with KRE Corporate Recovery appointed as licensed insolvency practitioners on
22 July 2024. It is currently anticipated there will not be surplus funds to
pay a distribution to any class of creditor.

 

Edward Wardle is a 49% shareholder in Northern Standard Limited, which is
interested in 150,000,000 ordinary shares in the Company. Northern Standard
Limited is a 51% owned subsidiary of Tracarta Limited, a company in which John
Wardle, Edward Wardle's father, has a beneficial interest.

 

In addition, Mr Wardle personally holds 18,750,000 warrants to subscribe for
new ordinary shares in the Company exercisable at 0.4p per share which expire
on 4 April 2030.

 

For more information please contact:

 

 N4 Pharma plc

 Nigel Theobald, CEO                                                       Via N4 Pharma Investor Hub: investors.n4pharma.com

                                                                         (https://investors.n4pharma.com/)
 Luke Cairns, Executive Director

                                                                         https://investors.n4pharma.com/link/0rJNYr
 Submit your questions directly to the management team via the N4 Pharma   (https://investors.n4pharma.com/link/0rJNYr)
 Investor Hub

 SP Angel Corporate Finance LLP                                            Tel: +44 (0)20 3470 0470

 Nominated Adviser and Joint Broker

 Matthew Johnson/Jen Clarke (Corporate Finance)

 Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking)
 Turner Pope Investments (TPI) Limited                                     Tel: +44 (0)20 3657 0050

 Joint Broker

 Andy Thacker

 James Pope
 Northstar Communications Limited                                          Tel: +44 (0)113 730 3896

 Investor Relations

 Sarah Hollins

 

About N4 Pharma

N4 Pharma is a pre-clinical biotech company developing Nuvec®, its
proprietary gene delivery system, to enable advanced therapies for cancer and
other diseases.

 

RNA therapeutics are set to impact the treatment of a wide range of diseases
and Nuvec® has several key advantages for RNA gene delivery including the
ability to deliver multiple RNA therapies in a single particle, ease of
manufacturing, protection of the RNA payload to allow for oral delivery, no
unwanted immune response and excellent stability and storage.

 

N4 Pharma is building out its preclinical data set and working towards
first-in-human clinical data to support significant licensing deals for its
Nuvec® platform with gene therapy partners.

 

N4 Pharma's lead programme, N4 101, is an oral anti-inflammatory product for
IBD which serves as a proof-of-concept programme showcasing all the benefits
of the Nuvec® platform.

 

For further information on the Company visit www.n4pharma.com
(http://www.n4pharma.com) or sign up at
https://investors.n4pharma.com/auth/signup
(https://investors.n4pharma.com/auth/signup) .

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAUBVSRVBUBRAR